

Table 2**Pharmacotherapy for non-alcoholic fatty liver disease**

Recommended treatment (under hepatologist supervision)	Dose	Patient group	Outcomes
Vitamin E	800 units/day	*NASH	Improvement in fatty infiltration and inflammation
Pioglitazone	30-45 mg/day	NASH	Improvement in fatty infiltration and inflammation
Potential treatments			
Lanifibranor, a pan-PPAR agonist	1,200 mg/day (in phase III trials)	NASH	Improvement of NASH
Obeticholic acid, a farnesoid X receptor agonist	25 mg/day	NASH and significant fibrosis	Improvement in fibrosis
Semaglutide, a GLP-1 receptor agonist	Subcutaneous injection once a day	NASH	Improvement in NASH
Treatments with no proven benefit			
Metformin	500-2,000 mg/day	NASH without diabetes or diabetes without insulin treatment	Null
Ursodeoxycholic acid	10-35 mg/kg/day	NASH	Null
Orlistat	120 mg tds	NASH	Null

* NASH = non-alcoholic steatohepatitis